236 related articles for article (PubMed ID: 33675181)
1. Prognostic impact of Notch1 receptor and clinicopathological High-Risk Predictors in lacrimal gland adenoid cystic carcinoma.
Anjum S; Sen S; Pushker N; Bajaj MS; Kashyap S; Bakhshi S; Chosdol K; Meel R; Sharma MC
Acta Ophthalmol; 2021 Dec; 99(8):e1467-e1473. PubMed ID: 33675181
[TBL] [Abstract][Full Text] [Related]
2. Vascular endothelial growth factor (VEGF) and hypoxia inducible factor-1 alpha (HIF-1ɑ) in lacrimal gland Adenoid cystic carcinoma: Correlation with clinical outcome.
Anjum S; Sen S; Chosdol K; Bakhshi S; Kashyap S; Pushker N; Bajaj MS; Meel R; Sharma MC
Ann Diagn Pathol; 2022 Feb; 56():151846. PubMed ID: 34749048
[TBL] [Abstract][Full Text] [Related]
3. Adenoid cystic carcinoma of the lacrimal gland is frequently characterized by MYB rearrangement.
Chen TY; Keeney MG; Chintakuntlawar AV; Knutson DL; Kloft-Nelson S; Greipp PT; Garrity JA; Salomao DR; Garcia JJ
Eye (Lond); 2017 May; 31(5):720-725. PubMed ID: 28085142
[TBL] [Abstract][Full Text] [Related]
4. Expression of metabolism-related proteins in lacrimal gland adenoid cystic carcinoma.
Koo JS; Yoon JS
Am J Clin Pathol; 2015 Apr; 143(4):584-92. PubMed ID: 25780012
[TBL] [Abstract][Full Text] [Related]
5. Survival outcomes of eye-sparing surgery for adenoid cystic carcinoma of lacrimal gland.
Hung JY; Wei YH; Huang CH; Chen LW; Fuh CS; Liao SL
Jpn J Ophthalmol; 2019 Jul; 63(4):344-351. PubMed ID: 31134459
[TBL] [Abstract][Full Text] [Related]
6. Prognostic factors for local recurrence and survival and impact of local treatments on survival in lacrimal gland carcinoma.
Ford JR; Rubin ML; Frank SJ; Ning J; Debnam JM; Bell D; El-Naggar A; Ferrarotto R; Esmaeli B
Br J Ophthalmol; 2021 Jun; 105(6):768-774. PubMed ID: 32680839
[TBL] [Abstract][Full Text] [Related]
7. Expression of Autophagy and Reactive Oxygen Species-Related Proteins in Lacrimal Gland Adenoid Cystic Carcinoma.
Koo JS; Kim JW; Yoon JS
Yonsei Med J; 2016 Mar; 57(2):482-9. PubMed ID: 26847304
[TBL] [Abstract][Full Text] [Related]
8. [The expression of MMP-2 and MMP-9 in adenoid cystic carcinoma of lacrimal gland].
Zhang L; Zhang H; Song GX; Lin TT; Xu GC; Zhu LM
Zhonghua Yan Ke Za Zhi; 2013 Jan; 49(1):58-63. PubMed ID: 23601468
[TBL] [Abstract][Full Text] [Related]
9. Long-Term Outcomes of Eye-Sparing Surgery for Adenoid Cystic Carcinoma of Lacrimal Gland.
Han J; Kim YD; Woo KI; Sobti D
Ophthalmic Plast Reconstr Surg; 2018; 34(1):74-78. PubMed ID: 28221296
[TBL] [Abstract][Full Text] [Related]
10. Adenoid Cystic Carcinoma from the salivary and lacrimal glands and the breast: Different clinical outcomes to the same tumor.
Emerick C; Mariano FV; Vargas PA; Nör JE; Squarize CH; Castilho RM
Crit Rev Oncol Hematol; 2022 Nov; 179():103792. PubMed ID: 35973662
[TBL] [Abstract][Full Text] [Related]
11. [Imaging feature and clinical histological analysis of 12 adenoid cystic carcinoma of the lacrimal gland].
Wang F; Sun FY; Guo XX; Xia S; Tang DR
Zhonghua Yan Ke Za Zhi; 2013 Jan; 49(1):47-51. PubMed ID: 23601466
[TBL] [Abstract][Full Text] [Related]
12. Diffuse Staining for Activated NOTCH1 Correlates With NOTCH1 Mutation Status and Is Associated With Worse Outcome in Adenoid Cystic Carcinoma.
Sajed DP; Faquin WC; Carey C; Severson EA; H Afrogheh A; A Johnson C; Blacklow SC; Chau NG; Lin DT; Krane JF; Jo VY; Garcia JJ; Sholl LM; Aster JC
Am J Surg Pathol; 2017 Nov; 41(11):1473-1482. PubMed ID: 28914715
[TBL] [Abstract][Full Text] [Related]
13. Assessment of p16 expression and HPV infection in adenoid cystic carcinoma of the lacrimal gland.
Wang Y; Tian Y; Lin J; Chen L; Wang L; Hao P; Han R; Ying M; Li X; Tang X
Mol Vis; 2018; 24():143-152. PubMed ID: 29430168
[TBL] [Abstract][Full Text] [Related]
14. Expression patterns and prognostic significance of inhibitor of apoptosis proteins in adenoid cystic carcinoma and pleomorphic adenoma of lachrymal gland.
Liao Y; Zeng H; Wang X; Huang Y; Chen N; Ge B; Tang L; Luo Q
Exp Eye Res; 2009 Jan; 88(1):4-11. PubMed ID: 18955046
[TBL] [Abstract][Full Text] [Related]
15. Adenoid cystic carcinoma of the lacrimal gland: role of nuclear survivin (BIRC5) as a prognostic marker.
Mulay K; Puthyapurayil FM; Mohammad JA; Hasnat Ali M; Honavar SG; Reddy VA
Histopathology; 2013 May; 62(6):840-6. PubMed ID: 23611357
[TBL] [Abstract][Full Text] [Related]
16. Activating NOTCH1 Mutations Define a Distinct Subgroup of Patients With Adenoid Cystic Carcinoma Who Have Poor Prognosis, Propensity to Bone and Liver Metastasis, and Potential Responsiveness to Notch1 Inhibitors.
Ferrarotto R; Mitani Y; Diao L; Guijarro I; Wang J; Zweidler-McKay P; Bell D; William WN; Glisson BS; Wick MJ; Kapoun AM; Patnaik A; Eckhardt G; Munster P; Faoro L; Dupont J; Lee JJ; Futreal A; El-Naggar AK; Heymach JV
J Clin Oncol; 2017 Jan; 35(3):352-360. PubMed ID: 27870570
[TBL] [Abstract][Full Text] [Related]
17. Multimodal therapy in the management of lacrimal gland adenoid cystic carcinoma.
Yang J; Zhou C; Wang Y; Fan X; Jia R
BMC Ophthalmol; 2019 Jun; 19(1):125. PubMed ID: 31176360
[TBL] [Abstract][Full Text] [Related]
18. Long-term outcomes of neoadjuvant intra-arterial cytoreductive chemotherapy for lacrimal gland adenoid cystic carcinoma.
Tse DT; Kossler AL; Feuer WJ; Benedetto PW
Ophthalmology; 2013 Jul; 120(7):1313-23. PubMed ID: 23582989
[TBL] [Abstract][Full Text] [Related]
19. Clinical and microdissection genotyping analyses of the effect of intra-arterial cytoreductive chemotherapy in the treatment of lacrimal gland adenoid cystic carcinoma.
Tse DT
Trans Am Ophthalmol Soc; 2005; 103():337-67. PubMed ID: 17057810
[TBL] [Abstract][Full Text] [Related]
20. Genome Sequencing and Apoptotic Markers to Assess Treatment Response of Lacrimal Gland Adenoid Cystic Carcinoma to Intra-Arterial Cytoreductive Chemotherapy.
Yu MD; Men CJ; Do H; Colevas AD; Lin JH; Egbert PR; Tse DT; Kossler AL
Ophthalmic Plast Reconstr Surg; 2022 Mar-Apr 01; 38(2):e44-e47. PubMed ID: 34798653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
